Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Oversteps Its Bounds In Guidance On Research-Only Tests, Firms Say

This article was originally published in The Gray Sheet

Executive Summary

Diagnostics companies say recent draft guidance on research-use and investigational tests oversteps FDA’s authorities by asking firms to police how customers ultimately use these products.
Advertisement

Related Content

Knowledge Is Not Enough For Enforcement In FDA’s Final Research-Use Dx Guidance
Knowledge Is Not Enough For Enforcement In FDA’s Final Research-Use Dx Guidance
Attorneys See FDA Rulemaking By Guidance In NDI Notification Draft
Attorneys See FDA Rulemaking By Guidance In NDI Notification Draft
Attorneys See FDA Rulemaking By Guidance In NDI Notification Draft
Attorneys See FDA Rulemaking By Guidance In NDI Notification Draft
Labs Fear FDA’s Research-Use Dx Policy Could Shutter Some Testing Services
Labs Fear FDA’s Research-Use Dx Policy Could Shutter Some Testing Services
Makers Of Research-Only Tests Must Respond To Inappropriate Use – FDA Draft Guidance
Makers Of Research-Only Tests Must Respond To Inappropriate Use – FDA Draft Guidance

Topics

Advertisement
UsernamePublicRestriction

Register

MT030560

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel